Maruyama 2008.
| Methods |
RANDOMISED CONTROLLED CLINICAL TRIAL (RCT): yes, parallel RCT RANDOMISATION RATIO: equal ratio assumed (not stated in manuscript) NON‐INFERIORITY DESIGN: no EQUIVALENCE DESIGN: no ETHICS APPROVAL OBTAINED: yes PATIENT CONSENT OBTAINED: yes BLINDING OF PATIENT (P), EDUCATOR (E), RESEARCHER (R): P = no, E = no, R = unclear ANALYSIS BY INTENTION TO TREAT: No, not stated in the manuscript POWER CALCULATION: yes |
|
| Participants |
WHO PARTCIPATED: SEX (female% / male%): Insulin 43%F (13/30): 57% M (17/30), SU 46% F (14/30) : 53% M(16/30) AGE (mean years (SD)): Insulin: 54 years (13), SU 51 yrs (13) ETHNIC GROUPS (%): not stated DURATION OF DISEASE (mean years (SD)): insulin 1.7 yrs (1.9), SU 1.9 yrs (1.7) INCLUSION CRITERIA: (1) diagnosis of diabetes according to ADA criteria (2) not treated with insulin at least 6 months after diagnosis of diabetes (3) positive GADA in 2 samples taken within 2 months (4) disease duration < 10 years (5) patients were unrelated EXCLUSION CRITERIA: (1) history of ketonuria, diabetic ketoacidosis, marked hyperglycaemia requiring insulin, (2) renal or hepatic dysfunction affecting C‐peptide clearance and glucose tolerance, DIAGNOSTIC CRITERIA: Diabetes diagnosed according to American Diabetes Association (ADA) standards CO‐MORBIDITIES:Not given CO‐MEDICATIONS: Not given NUMBER: Insulin 30, SU 30 LOSS TO FOLLOW‐UP: 0% |
|
| Interventions |
NUMBER OF STUDY CENTRES:7 COUNTRY/ LOCATION: Japan SETTING: out‐patient INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY): subcutaneous insulin therapy CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): sulphonylurea (glibenclamide) TREATMENT BEFORE STUDY:None TITRATION PERIOD: None. |
|
| Outcomes |
PRIMARY OUTCOME(S) (as stated in the publication):Not stated but objectives states "to examine the ability of insulin to prevent progressive beta‐cell dysfunction in SPIDDM" SECONDARY OUTCOMES (as stated in the publication):Not stated ADDITIONAL OUTCOMES: Collected at baseline and 4 years. 1. Stimulated C‐peptide and change in C‐peptide response (ng/ml), 2. Blood glucose, 3. HbA1c (%), 4. GADA (U/ml) 5. insulin dependent state 6. BMI |
|
| Study details |
DURATION OF INTERVENTION: 5 years DURATION OF FOLLOW‐UP: 5 years (with 3‐monthly assessments) RUN‐IN PERIOD: None |
|
| Publication details |
LANGUAGE OF PUBLICATION: English COMMERCIAL FUNDING: not reported NON‐COMMERCIAL FUNDING: not reported PUBLICATION STATUS (PEER REVIEW JOURNAL): yes PUBLICATION STATUS (JOURNAL SUPPLEMENT): no PUBLICATION STATUS (ABSTRACT): Full paper |
|
| Stated aim for study | Quote "to examine the ability of insulin to prevent progressive ß‐cell dysfunction in SPIDDM " | |
| Notes | Comment: This is a follow‐up study from Kobayashi 1996 and Maruyama 2003 | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Patients were randomly assigned using a centralized, masked‐draw system. |
| Allocation concealment (selection bias) | Low risk | Unblinded |
| Blinding (performance bias and detection bias) All outcomes | Unclear risk | Unblinded but there was no evidence that the analyst was blinded |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No problems identified |
| Selective reporting (reporting bias) | Low risk | No problems identified |
| Other bias | Unclear risk | Sponsorship not reported |